IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced plans to offer up to $300 million in common stock and pre-funded warrants in an underwritten public offering. The South San Francisco-based precision medicine oncology company also intends to grant underwriters a 30-day option to purchase up to $45 million of additional common stock shares.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are serving as joint book-running managers for the offering. The securities will be offered under an automatically effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

The company stated the offering is subject to market and other conditions, with no assurance regarding completion timing or final terms. IDEAYA noted that certain investors may receive pre-funded warrants in lieu of common stock shares.

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available through the commission's website. Copies may also be obtained through the underwriters upon request.

IDEAYA focuses on developing precision medicine therapies for cancer, with a pipeline centered on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications. The company integrates small-molecule drug discovery, structural biology, and bioinformatics with translational biomarker capabilities.

The announcement follows standard disclosure requirements for public offerings, with the company emphasizing that the press release does not constitute an offer to sell securities in jurisdictions where such offers would be unlawful.